Juan Andres - 17 Sep 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
17 Sep 2021
Net transactions value
-$4,157,200
Form type
4
Filing time
21 Sep 2021, 16:17:13 UTC
Previous filing
17 Sep 2021
Next filing
24 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 17 Sep 2021 Direct F1
transaction MRNA Common Stock Sale $2,191,200 -5,000 -100% $438.24 0 17 Sep 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 20 Sep 2021 Direct F1
transaction MRNA Common Stock Sale $2,088,100 -5,000 -100% $417.62 0 20 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.9% $0.000000 254,822 17 Sep 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -2% $0.000000 249,822 20 Sep 2021 Common Stock 5,000 $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.

Remarks:

Chief Technical Operations and Quality Officer